Tenderwize
Wróć do wyszukiwania

Open-house rebate agreements for Etanercept

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Sep 05, 2026 · 8 days left·Open·Supplies·Framework
Zarejestruj się, aby zapisaćOpen documents
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Etanercept, ATC L04AB01

52/100

Ocena szansy

Needs reviewMedium complexity
SuppliesFrameworkOpen
Skąd ta ocena?

Szansa

52 / 100

Złożoność

58 / 100

Czynniki ryzyka

For paper submissions, the notice requires duplicate originals and a prior fax/scan/email/portal transmission only pres...

Participation is limited to pharmaceutical companies and requires a signed reliability self-declaration.

Submission deadline in 8 days

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Oct 2026
  • Non-exclusive rebate agreements for the medicinal product Etanercept, ATC L04AB01.
  • Open-house model with identical, pre-set contract terms for all eligible pharmaceutical companies.
Pokaż pełne podsumowanie

Open-house supply arrangement for pharmaceutical products: non-exclusive rebate agreements for Etanercept (ATC L04AB01) offered by AOK Bayern to all interested pharmaceutical companies that meet the stated suitability requirement. This is explicitly described as a non-competitive open-house model with no selection decision and no negotiated terms. Contracting is possible throughout the term, with the latest contract conclusion date on 2026-09-05. Submission can be made electronically with a qualified electronic signature or in paper form; documents not in German must be submitted with a German translation.

Ryzyka

For paper submissions, the notice requires duplicate originals and a prior fax/scan/email/portal transmission only pres...

Participation is limited to pharmaceutical companies and requires a signed reliability self-declaration.

Submission deadline in 8 days

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Eligibility

  • Only pharmaceutical companies are eligible as potential contract partners.

Administrative

  • Submission of a completed and signed self-declaration on reliability (Eigenerklärung zur Zuverlässigkeit).
  • Submission of the completed and signed contract and the completed and signed annex 'Festlegung der vertragsgegenständlichen Arzneimittel'.

Zamawiający

Lokalizacja

München, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE811695320

Działalność

Health

Części (1)

LOT-0001

Open-house rebate agreements for Etanercept

Open-house supply lot for non-exclusive rebate agreements concerning the active substance Etanercept (ATC L04AB01). The notice states that all interested pharmaceutical companies meeting the suitability requirement may join on identical, non-individually negotiable terms. Place of performance is Germany, specifically DE212 (Bavaria/Munich region in the notice metadata).

SuppliesFrameworkEU fundedElectronic submission

Lokalizacja

DE212, Germany

Czas trwania

Oct 2024 - Oct 2026

Kategoria

Pharmaceutical products

Termin

Deadline Sep 05, 2026

Szczegóły zamówienia

Data publikacji
16 Sep 2024
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
557440-2024

Dokumenty (2)

Dokument zamówienia 1Portal składania ofert 1

Podobne przetargi

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30